Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Operates in Healthcare Services — In-patient & out-patient services. Per the activity note to the FY2024 annual report, the company provides comprehensive medical services with multiple clinics across southwestern Georgia regions. Founded in 2011; operates clinics in Lanchkhuti, Ozurgeti, Chokhatauri, and Kaspi regions.
Subsidiary of Aversi-Pharma (100.0%)
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 85.6% | 84.7% | 83.8% | 82.9% | 79.2% | 79.0% | 76.5% | 79.7% |
| EBITDA Margin | 75.1% | 19.1% | 15.8% | 26.1% | 31.3% | 20.2% | -13.1% | -1.1% |
| EBITDAR | 9,692 | 2,847 | 2,564 | 4,362 | 7,355 | 3,413 | -1,295 | -73 |
| EBITDAR Margin | 76.4% | 20.2% | 16.0% | 26.3% | 31.5% | 20.5% | -12.6% | -0.6% |
| EBIT Margin | 66.8% | 11.5% | 6.9% | 17.5% | 28.1% | 14.6% | -24.7% | -13.0% |
| Net Profit Margin | 12.5% | 11.5% | 6.3% | 17.4% | 30.5% | 14.2% | -24.0% | -13.1% |
| Operating Expense % of Sales | 10.5% | 65.6% | 69.0% | 58.0% | 48.4% | 60.1% | 91.4% | 82.2% |
| Returns | ||||||||
| Return on Assets (ROA) | 8.5% | 7.2% | 4.1% | 11.4% | 24.0% | 8.3% | -10.9% | -6.8% |
| Return on Equity (ROE) | 9.5% | 8.6% | 4.9% | 12.4% | 26.4% | 8.7% | -12.0% | -8.0% |
| ROIC [EBIT / Invested Capital] | 52.6% | 8.8% | 5.2% | 13.4% | 25.4% | 9.6% | -12.2% | -7.8% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 0.0% | 0.0% | 3.1% | 0.3% | 0.7% | 0.5% | 0.9% | 1.2% |
| Debt-to-Equity | 0.00x | 0.00x | 0.04x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.30x | 0.02x | 0.03x | 0.05x | N/A | N/A |
| Equity-to-Assets | 89.8% | 84.6% | 84.3% | 92.4% | 91.1% | 95.0% | 91.2% | 85.5% |
| Net Debt | -524 | -456 | 628 | -1,601 | -1,134 | -2,150 | 151 | 265 |
| Cash & Equivalents | 524 | 456 | 122 | 1,682 | 1,327 | 2,307 | 63 | 27 |
| Total Debt | N/A | N/A | 751 | 80 | 193 | 157 | 214 | 292 |
| Liquidity & working capital | ||||||||
| Current Ratio | 3.20x | 1.41x | 1.63x | 3.68x | 4.28x | 10.03x | 1.55x | 0.95x |
| Quick Ratio | 2.94x | 1.31x | 1.51x | 3.37x | 3.97x | 9.69x | 1.33x | 0.85x |
| Cash Ratio | 0.29x | 0.14x | 0.04x | 0.89x | 0.53x | 1.75x | 0.04x | 0.01x |
| Total Current Assets | 5,685 | 4,750 | 5,300 | 6,972 | 10,654 | 13,193 | 2,785 | 3,165 |
| Total Current Liabilities | 1,778 | 3,368 | 3,254 | 1,896 | 2,490 | 1,315 | 1,791 | 3,331 |
| Inventory | 462 | 346 | 402 | 590 | 756 | 452 | 400 | 338 |
| Trade Receivables | 4,699 | 3,948 | 4,776 | 4,700 | 8,571 | 10,434 | 2,321 | 2,800 |
| Trade Payables | 1,778 | 3,368 | 2,286 | 1,093 | 1,215 | 705 | 1,265 | 2,470 |
| Net Working Capital | 3,907 | 1,383 | 2,046 | 5,077 | 8,164 | 11,878 | 993 | -166 |
| Net Working Capital % of Revenue | 30.8% | 9.8% | 12.8% | 30.6% | 34.9% | 71.2% | 9.7% | -1.3% |
| Trade Working Capital | 3,383 | 926 | 2,892 | 4,198 | 8,112 | 10,181 | 1,456 | 668 |
| Trade Working Capital % of Revenue | 26.7% | 6.6% | 18.1% | 25.3% | 34.7% | 61.0% | 14.2% | 5.3% |
| Change in Trade Working Capital | N/A | -2,456 | 1,965 | 1,306 | 3,914 | 2,068 | -8,725 | -788 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 3.96x | 6.25x | 6.45x | 4.79x | 6.42x | 7.76x | 6.03x | 7.57x |
| Days Inventory Outstanding (DIO) | 92.2 | 58.4 | 56.6 | 76.2 | 56.8 | 47.1 | 60.6 | 48.2 |
| Receivables Turnover | 2.70x | 3.57x | 3.35x | 3.53x | 2.73x | 1.60x | 4.42x | 4.51x |
| Days Sales Outstanding (DSO) | 135.1 | 102.3 | 109.1 | 103.4 | 133.9 | 228.3 | 82.6 | 81.0 |
| Payables Turnover | 1.03x | 0.64x | 1.13x | 2.59x | 4.00x | 4.97x | 1.91x | 1.04x |
| Days Payable Outstanding (DPO) | 354.8 | 568.5 | 322.1 | 140.9 | 91.4 | 73.4 | 191.4 | 352.0 |
| Cash Conversion Cycle | -127.5 days | -407.8 days | -156.4 days | 38.6 days | 99.3 days | 201.9 days | -48.2 days | -222.8 days |
| Asset Turnover | 0.69x | 0.63x | 0.66x | 0.66x | 0.79x | 0.58x | 0.45x | 0.52x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 1,678 | 3,515 | 1,956 | 3,393 | 5,241 | 7,569 | 6,743 | 998 |
| Free Cash Flow (OCF − Capex proxy) | 1,678 | -728 | -899 | 1,731 | 3,184 | 3,216 | 2,067 | -1,806 |
| Cash Conversion (OCF / EBITDA) | 17.6% | 130.8% | 77.5% | 78.5% | 71.6% | 224.7% | N/A | N/A |
| Dividends Declared | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Payout Ratio | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →